Multivariate Cox proportional hazard analysis
| Variable | Overall survival | Relapse-free survival | ||
|---|---|---|---|---|
| HR (95% Cl) | p | HR (95% Cl) | p | |
| CA125 | 1 (1–1) | 0.495 | 1 (1–1) | 0.98 |
| Stage | 0.5 | 0.98 | ||
| Stage I | 1 | 1 | ||
| Stage II | 0.76 (0.14–4.18) | 0.755 | 1.3 (0.45–3.77) | 0.627 |
| Stage III | 2.21 (0.76–6.41) | 0.145 | 1.75 (0.79–3.87) | 0.165 |
| Stage IV | 4.89 (1.33–17.9) | 0.017 | 2.84 (0.96–8.4) | 0.06 |
| Debulking | 0.39 | 0.9 | ||
| Debulking R0 | 1 | 1 | ||
| Debulking R1 | 0.62 (0.21–1.84) | 0.386 | 0.95 (0.4–2.24) | 0.91 |
| Debulking R2 | 1.35 (0.8–2.27) | 0.262 | 1.92 (1.21–3.06) | 0.006 |
| Age | 1 (0.98–1.03) | 0.743 | 1.01 (0.99–1.03) | 0.508 |
| CALR | 0.96 (0.94–0.99) | 0.0003 | 0.97 (0.96–0.99) | 0.002 |
| DC-LAMP summary | 0.8 (0.7–0.91) | 0.001 | 0.97 (0.94–1.0) | 0.12 |
| CD8 summary | 0.99 (0.99–0.99) | 0.0007 | 0.99 (0.99–1) | 0.13 |
| CD20 | 0.23 (0.3–1.54) | 0.13 | 1 (0.33–1.5) | 0.86 |
| NKp46 | 1.08 (0.9–1.3) | 0.37 | 1.11 (0.93–1.35) | 0.24 |